Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
Legend Biotech Corp. (LEGN.US) on Tuesday reported strong double-digit revenue growth in last year’s fourth quarter on solid gains for its core Carvykti cancer treatment, lifting the company to a…
BRIEF: Hutchmed’s revenue drops 13% in 2025
Drug developer Hutchmed China Ltd. (HCM.US; 0013.HK) said on Thursday its revenue fell 13% in 2025 to $548.5 million from $630.2 million the previous year, as its profit rose sharply…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
Recent Articles
RELATED ARTICLES
-
Legend Bio CEO resigns, shares tumble
- BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
iQiyi names Tian Ying as new CFO
IQ.US
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Cancer screening company faces tough IPO test as market cools
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
